Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal - An In vitro Study

Helicobacter

Volumn 21, Issue 2, 2016, Pages 143-152

  Saniee, Parastoo ^a   Shahreza, Somayeh ^a   Siavoshi, Farideh ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Growth; Helicobacter pylori; Morphology; Negative effect; PPIs; Urease

Indexed keywords

AGAR; AMOXICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; FURAZOLIDONE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; POLYMYXIN B; PROTON PUMP INHIBITOR; TETRACYCLINE; TRIMETHOPRIM; UREASE; VANCOMYCIN; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRUCTURES; BACTERIAL VIABILITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DYSPEPSIA; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LETHALITY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAPID UREASE TEST; STOMACH BIOPSY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; UREASE; YOUNG ADULT;

EID: 84959890978     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12246     Document Type: Article

References (46)

1. +- ATPase by omeprazole. Biochem Pharmacol 1988;37:2543-9.
2. Sachs G, Shin JM, Munson K, Vagin O, Lambrecht N, Scott DR, Weeks DL, Melchers K. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1383-401.
3. +)ATPase. Nature 1981;290:159-61.
4. Marshall B, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
5. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H, K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007;41(Suppl 2):S226-42.
6. Biasco G, Miglioli M, Barbara L, Corinaldesi R, Febo G. Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. The Lancet 1989;334:1403.
7. Labenz J, Stolte M, Domian C, Bertrams J, Borsch G. High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion 1995;56:14-20.
8. Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998;27:S163-9.
9. Nakao M, Tada M, Tsuchimori K, Uekata M. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1995;14:391-9.
10. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
11. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:769-74.
12. Chen T, Meng X, Zhang H, Tsang RW, Tsang T-K. Comparing multiplex PCR and rapid urease test in the detection of H. pylori in patients on proton pump inhibitors. Gastroenterol Res Pract 2012;2012:1-5.
13. Goldstein NS. Chronic inactive gastritis and coccoid Helicobacter pylori in patients treated for gastroesophageal reflux disease or with H pylori eradication therapy. Am J Clin Pathol 2002;118:719-26.
14. Andersen LP, Dorland A, Karacan H, Colding H, Nilsson HO, Wadstrom T, Blom J. Possible clinical importance of the transformation of Helicobacter pylori into coccoid forms. Scand J Gastroenterol 2000;35:897-903.
15. Suerbaum S, Leying H, Klemm K, Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991;10:92-3.
16. Megraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. J Clin Gastroenterol 1995;20(Suppl 1):S24-7.
17. Sjostrom JE, Berglund ML, Fryklund J, Kühler T, Larsson H. Factors affecting the antibacterial activity of omeprazole and structural analogues in vitro. Acta Gastroenterol Belg 1993;56:144.
18. Kuhler T, Fryklund J, Bergman NA, Weilitz J, Larson H.Omeprazole and analogues inhibit urea dependent ammonia production by. Helicobacter pylori. 1993.
19. Belli WA, Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob Agents Chemother 1995;39:1717-20.
20. Mauch F, Malfertheiner P, Bode G. Identification of an ATPase-system of Helicobacter pylori and its affection by benzimidazoles. Acta Gastroenterol Belg 1993;56:53.
21. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989;248:799-805.
22. Nagata K, Takagi E, Tsuda M, Nakazawa T, Satoh H, Nakao M, Okamura H, Tamura T. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother 1995;39:567-70.
23. Attumi TA, Graham DY. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol 2011;9:373-5.
24. Siavoshi F, Saniee P, Khalili-Samani S, Hosseini F, Malakutikhah F, Mamivand M, Shahreza S, Sharifi AH. Evaluation of methods for H. pylori detection in PPI consumption using culture, rapid urease test and smear examination. Ann Transl Med 2015;3:11.
25. Perna F, Ricci C, Gatta L, Bernabucci V, Cavina M, Miglioli M, Vaira D. Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2005;51:247-54.
26. Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med 2015;3:9.
27. Bury-Mone S, Kaakoush NO, Asencio C, Megraud F, Thibonnier M, De Reuse H, Mendz GL. Is Helicobacter pylori a true microaerophile? Helicobacter 2006;11:296-303.
28. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994;107:1573-8.
29. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. Arch Iran Med 2010;13:177-87.
30. Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med 2006;9:308-14.
31. Gatta L, Perna F, Figura N, Ricci C, Holton J, D'Anna L, Miglioli M, Vaira D. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003;51:439-42.
32. Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS, El-Zimaity HM. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003;98:1005-9.
33. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996;10:289-93.
34. Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, Jones PH, Trowell JE. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991;5:309-13.
35. Parente F, Sainaghi M, Sangaletti O, Imbesi V, Maconi G, Anderloni A, Bianchi Porro G. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther 2002;16:553-7.
36. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998;3:21-7.
37. Sjostrom JE, Kuhler T, Larsson H. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 1997;41:1797-801.
38. Larsson H, Fryklund J, Kühler T, O'Rourke J, Lee A. Omeprazole has no antibacterial effect in vivo in the Helicobacter felis infected rat. Acta Gastroenterol Belg 1993;56:140.
39. Sturr MG, Marquis RE. Comparative acid tolerances and inhibitor sensitivities of isolated F-ATPases of oral lactic acid bacteria. Appl Environ Microbiol 1992;58:2287-91.
40. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy. Int J Clin Pract 2000;54:537-41.
41. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266-80.
42. Saito N, Konishi K, Sato F, Kato M, Takeda H, Sugiyama T, Asaka M. Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. J Infect 2003;46:49-55.
43. Sisto F, Brenciaglia MI, Scaltrito MM, Dubini F. Helicobacter pylori: ureA, cagA and vacA expression during conversion to the coccoid form. Int J Antimicrob Agents 2000;15:277-82.
44. van Amsterdam K, Bart A, van der Ende A. A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother 2005;49:1477-82.
45. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998;27(Suppl 1):S32-41.
46. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50.